GENOCEA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | 0.00% |
|
0.00% | 0.00% |
| 2023 | Genocea Biosciences, Inc. Went Out of Business | CI |
| 2023 | Liquidation Plan Approved for Genocea Biosciences, Inc. | CI |
Valuation
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 116.9 | 32.89 | 24.84 | 54.13 | 125 | 66.64 |
| Enterprise Value (EV) 1 | 70.51 | 34.93 | 13.31 | 33.92 | 69.06 | 46.67 |
| P/E ratio | -2.35 x | -0.59 x | -0.85 x | -1.1 x | -2.18 x | -2.4 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 498 x | - | - | - | 91.9 x | 40.6 x |
| EV / Revenue | 300 x | - | - | - | 50.8 x | 28.4 x |
| EV / EBITDA | -1.47 x | -0.68 x | -0.34 x | -0.89 x | -1.49 x | -0.89 x |
| EV / FCF | -2.55 x | -1.28 x | -0.51 x | -1.38 x | -2.61 x | -1.45 x |
| FCF Yield | -39.2% | -78.4% | -195% | -72.3% | -38.3% | -68.7% |
| Price to Book | 2.57 x | -5.5 x | 3.75 x | 2.33 x | 14.3 x | 2.49 x |
| Nbr of stocks (in thousands) | 3,547 | 3,545 | 10,828 | 26,150 | 51,635 | 57,445 |
| Reference price 2 | 32.96 | 9.280 | 2.294 | 2.070 | 2.420 | 1.160 |
| Announcement Date | 2/17/17 | 2/16/18 | 2/28/19 | 2/13/20 | 2/22/21 | 3/18/22 |
1USD in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.235 | - | - | - | 1.359 | 1.641 |
| EBITDA 1 | -48.12 | -51.42 | -38.83 | -38.29 | -46.45 | -52.34 |
| EBIT 1 | -49.84 | -52.64 | -39.52 | -38.99 | -46.99 | -53.19 |
| Operating Margin | -21,207.23% | - | - | - | -3,457.62% | -3,241.5% |
| Earnings before Tax (EBT) 1 | -49.57 | -56.71 | -27.81 | -38.95 | -43.71 | -33.2 |
| Net income 1 | -49.57 | -56.71 | -27.81 | -38.95 | -43.71 | -33.2 |
| Net margin | -21,094.89% | - | - | - | -3,216.63% | -2,022.91% |
| EPS 2 | -14.01 | -15.86 | -2.695 | -1.890 | -1.112 | -0.4841 |
| Free Cash Flow 1 | -27.62 | -27.37 | -25.94 | -24.53 | -26.42 | -32.08 |
| FCF margin | -11,752.93% | - | - | - | -1,944.42% | -1,954.98% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/17/17 | 2/16/18 | 2/28/19 | 2/13/20 | 2/22/21 | 3/18/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 2.04 | - | - | - | - |
| Net Cash position 1 | 46.4 | - | 11.5 | 20.2 | 55.9 | 20 |
| Leverage (Debt/EBITDA) | - | -0.0396 x | - | - | - | - |
| Free Cash Flow 1 | -27.6 | -27.4 | -25.9 | -24.5 | -26.4 | -32.1 |
| ROE (net income / shareholders' equity) | -73.3% | -287% | -4,329% | -241% | -257% | -184% |
| ROA (Net income/ Total Assets) | -34.2% | -75.3% | -102% | -58.2% | -38.9% | -43% |
| Assets 1 | 144.9 | 75.32 | 27.36 | 66.91 | 112.5 | 77.11 |
| Book Value Per Share 2 | 12.80 | -1.690 | 0.6100 | 0.8900 | 0.1700 | 0.4700 |
| Cash Flow per Share 2 | 7.710 | 3.420 | 2.430 | 1.460 | 1.500 | 0.6400 |
| Capex 1 | 2.54 | 1.18 | 0.24 | 1.14 | 2.59 | 3.29 |
| Capex / Sales | 1,080% | - | - | - | 190.21% | 200.37% |
| Announcement Date | 2/17/17 | 2/16/18 | 2/28/19 | 2/13/20 | 2/22/21 | 3/18/22 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 58 | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- GNCAQ Stock
- Financials Genocea Biosciences, Inc.
